Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.72 |
| ▸ | HTR3A | P46098 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KHK | P50053 | 1/20 | 0.43 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3467563 | 0.84 | HRH4 (1.00) | HRH4HTR3AKDM4EALDH1A1KMT2A | |
| SCHEMBL31749043 | 0.84 | HRH4 (0.74) | HRH4HTR3AKDM4EALDH1A1KMT2A | |
| SCHEMBL5237102 | 0.82 | HTR3A (0.72) | HRH4HTR3AKDM4EALDH1A1KMT2A | |
| SCHEMBL31214324 | 0.81 | HRH4 (0.70) | HRH4HTR3AKDM4EALDH1A1KMT2A | |
| SCHEMBL31214382 | 0.81 | HTR3A (0.70) | HRH4HTR3AKDM4EALDH1A1KMT2A | |
| SCHEMBL21548076 | 0.78 | HRH4 (0.69) | HRH4HTR3AKDM4EALDH1A1KMT2A | |
| Tert-Butyl Formate SCHEMBL27563615 | 0.76 | HRH4 (0.59) | HRH4HTR3AKDM4EALDH1A1KMT2A | |
| SCHEMBL27563614 | 0.74 | HRH4 (0.62) | HRH4HTR3AKDM4EALDH1A1KMT2A | |
| SCHEMBL5237605 | 0.74 | HRH4 (0.62) | HRH4HTR3ABCHEACHE | |
| SCHEMBL605362 | 0.73 | HRH4 (0.62) | HRH4HTR3AKDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| EP-1440976-B1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | HRH4 41/4885HTR3A 220/4885KDM4E 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.